OpGen, Inc. (OPGN) announced the publication of the final study results of the Unyvero HPN panel on Monday after which the OPGN stock price saw a jump of 36.73% at the time of closing. The OpGen stock remained green in the pre-market and reached $3.95 per share with a 47.39% gain as of this writing. Let’s understand more of it.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
OpGen Inc is a medicine company that develops and provides molecular products to cope with infectious diseases. The company’s recent publication demonstrated its Unyvero Hospitalized Pneumonia (HPN) takes just five hours to detect bacterial pathogens from the lower respiratory tract of hospitalized COVID-19 patients with pneumonia. The Unyvero HPN is a reliable panel as it provides accurate results with a high negative predictive value of 99.8% for the detection of pathogens.
There are many other advantages of the HPN panel as it enables detection of additional important pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Haemophilus influenzae, Stenotrophomonas maltophilia, and several others, thus resulting in higher diagnostic yield as compared Standard of Care (SoC) alone.
The company’s management said that they are happy about the strong performance of the HPN panel as it is necessary to detect bacterial pneumonia earlier in the hospital journey of COVID-19 patients.
About a week ago, the OpGen announced the regulatory approval of the Curetis Unyvero System as an in vitro diagnostics (IVD) instrument system in China by National Medical Products Administration, NMPA.
In the mid of February, OpGen subsidiary, Ares Genetics released its publications that demonstrated the best practice techniques AI-powered Prediction of Antibiotic Susceptibility Testing(AST) that resulted from whole-genome sequencing data.
Things are going well for OPGN stock after the release of its publication related to the HPN panel. Accurate results of HPN panel with less diagnostic time of bacterial co-infections in COVID-19 patients is a big success for the company as it will greatly contribute to the treatment of COVID-19 patients in the future. The rising OPGN stock price is now captivating the attention of investors and hence it can be a good bet for investors in the future.